Applied DNA Sciences Files 8-K

Ticker: BNBX · Form: 8-K · Filed: Jan 13, 2025 · CIK: 744452

Sentiment: neutral

Topics: disclosure, filing, sec

Related Tickers: APDN

TL;DR

APDN filed an 8-K on Jan 13, 2025, with Reg FD disclosures and exhibits.

AI Summary

Applied DNA Sciences, Inc. filed an 8-K on January 13, 2025, reporting information under Regulation FD and including financial statements and exhibits. The company, incorporated in Delaware, is listed under SIC code 8734 for Testing Laboratories and has its principal business address at 50 Health Sciences Drive, Stony Brook, NY.

Why It Matters

This filing provides updates and disclosures required by the SEC, which can offer insights into the company's regulatory compliance and financial reporting status.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K, which typically contains disclosures and exhibits rather than significant new financial or operational information.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing serves to report information under Regulation FD Disclosure and includes Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on January 13, 2025.

In which state was Applied DNA Sciences, Inc. incorporated?

Applied DNA Sciences, Inc. was incorporated in Delaware.

What is the company's business address?

The company's business address is 50 Health Sciences Drive, Stony Brook, New York 11790.

What is the Standard Industrial Classification (SIC) code for Applied DNA Sciences, Inc.?

The SIC code for Applied DNA Sciences, Inc. is 8734, which corresponds to Testing Laboratories.

Filing Stats: 544 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2025-01-13 08:45:49

Key Financial Figures

Filing Documents

01

Item 7.01. Regulation FD Disclosure. On January 13, 2025, Applied DNA Sciences, Inc. (the "Company") utilized a company presentation which may be used in presentations to investors from time to time. A copy of the presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information furnished in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise by reference into any filings of the Company made under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in the filing unless specifically stated so therein.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Company Presentation, dated January 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 13, 2025 APPLIED DNA SCIENCES, INC. By: /s/ James A. Hayward Name: James A. Hayward Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing